Introduction
T-cell lymphomas are a heterogeneous malignant disorder characterized by their variable morphology and different treatment responses even within a diagnostic category. The mechanisms involved in the T-cell lymphomagenesis and T-cell lymphoma progression are not well defined, in part due to the rarity of these neoplasms. 1 They are mainly classified as lymphoblastic T-cell lymphomas (LBL), derived from immature lymphocytes, and peripheral T-cell lymphomas (PTCL) arising from mature T lymphocytes. 2 PTCL, however, also constitutes a highly heterogeneous entity. Furthermore, these lymphomas are generally aggressive tumors with 5 year overall survival (OS) in less than 30% of cases.
In a recent paper, we described the general expression profile of T-cell lymphomas and identified the expression of the nuclear factor kappa B (NF-kB) pathway genes as one of the most important differences between LBL and PTCL lymphomas. 3 The NF-kB transcription factor is a key regulator of inflammatory and immune response genes. NF-kB transcriptional activity is mediated by heterodimers of the NF-kB family members, p50/ p105, p52/p100, p65/RelA, RelB or c-Rel. The main activated form of NF-kB is a heterodimer of the p65 subunit associated with either p50 or p52 subunits. NF-kB proteins are present in the cytoplasm in an inactive form, bound to inhibitory proteins called IkBs. 4 After activation by means of a wide range of stimuli, the IkB proteins are phosphorylated by the IkB kinase (IKK) complex, which comprises two active kinases, IKKa and IKKb, and a regulatory subunit, IKKg. Phosphorylation of IkBs leads to ubiquitinylation and subsequent proteolytic degradation of the inhibitors by the proteasome. The degradation of IkB allows NF-kB proteins to translocate to the nucleus and activate transcription of a large number of genes. 5, 6 NF-kB activation has been related to oncogenesis through several mechanisms. Numerous studies indicate that NF-kB activation can promote proliferative and antiapoptotic pathways, and its persistent activity is associated with tumor formation, growth, metastasis, and drug resistance in many cancer types, including B-cell lymphomas. 7 Constitutive activation of NF-kB as a result of chromosomal amplification, rearrangement of genes coding for Rel/NF-kB factors, activation of upstream signalling kinases or mutations inactivating inhibitory subunits are common features in some leukemias and lymphomas. 8, 9 However, in contrast to the evidence in favor that activation of NF-kB could lead to tumorigenesis, its activation is also related, under certain circumstances, to induction of apoptosis, and it is required for the normal function of the immune system and haematopoiesis. 10 Although NF-kB is rarely found to be constitutively active in normal cells, normal T-cells, B-cells or monocytes exhibit activated NF-kB when in a proliferative state. In fact, T lymphocytes undergo apoptosis induced after activation of these cells, via T-cell receptor (TCR) pathway, as well as upon DNA damage. It is known that apoptosis of T cells seems to be dependent on FasL expression and FasL-Fas engagement, leading to Fas-mediated apoptosis, and that this process requires activation of NF-kB. 11 Then, NFkB seems to have a dual role in promoting cellular proliferation through an inhibition of apoptosis, or inducing apoptosis under some circumstances.
Recent studies performed using DNA microarrays revealed differences among diffuse large B-cell lymphomas (DLBCL), allowing differentiation into at least two main subgroups, germinal center B (GCB) DLBCL and activated B-cell (ABC) DLBCL, based on their expression profiles. 12 High expression of NF-kB target genes associated to the ABC subgroup has been found and high NF-kB DNA-binding activity in this subgroup has been demonstrated. 13 Among T-cell lymphomas, NF-kB activation and high expression of NF-kB pathway genes characterize mycosis fungoides, one of the most common subtypes of cutaneous T-cell lymphomas (CTCL). 14, 15 In addition, NF-kB activation has been of interest in anaplastic large T-cell lymphomas. 16 Typically, they have CD30-expressing anaplastic cells, 17 present the t(2;5) 18 and have larger survival times. High expression of CD30, a member of the tumor necrosis factor receptor (TNFR) family, leads to the activation of NF-kB. 19 However, NF-kB activation has not been observed in some ALCL cells. 20 In addition, it has been described that the chimeric product NPM-ALK blocks the activation of NF-kB mediated by the CD30 signalling. 16 In this study, we used microarray expression analysis to assess differences in the expression of NF-kB pathway genes among peripheral T-cell lymphomas. We could differentiate two different subgroups of PTCL characterized by high or reduced expression of NF-kB pathway genes. Furthermore, the NF-kBbased differentiation of PTCL lymphomas seems to be an independent prognostic factor.
Materials and methods

Samples
Frozen tumor samples from 62 peripheral T-cell lymphomas were obtained to perform microarray expression analysis. We also analysed 14 LBL and seven cell lines (Jurkat, Karpas 45, Molt 16, Molt 13, Peer, Supt1 and KE37) to compare the expression of PTCL. Samples were collected from different hospitals belonging to the Spanish Cooperative Group of T-cell lymphomas. All these tumours were diagnosed according to the REAL and World Health Organization (WHO) classification criteria, and included 39 peripheral T lymphomas not otherwise characterized (PTCL, unsp), seven anaplastic large-cell lymphomas (ALCL), seven angioimmunoblastic lymphomas (AILT), four CTCL and five natural killer/T lymphomas (T-NK) ( Table 1) . Some of these cases, 34 PTCL and eight LBL tumors, have been previously reported by our group in an expression-profiling study. 3 The percentage of tumoral cells was estimated taking into account the morphology, the percentage of proliferating cells measured by Ki67 marker and the numbers of CD4-positive cells (Table 1) . Reactive lymph nodes (11 samples) were used as normal lymphoid tissue to compare with the tumors.
Immunohistochemical analysis was carried out using a tissue microarray (TMA) containing paraffin-embedded tissues from 46 T-cell lymphomas, most of them also included in the expression study (Table 2) . Representative tumoral areas were selected to construct the TMA. Additional independent paraffin-embedded tissue blocks from four LBL were used for immunohistochemical analysis (Table 2) . We also performed immunohistochemical analysis in seven LBL cell lines and in Karpas 299 anaplastic cell line, after processing cell suspensions into paraffin blocks with 10% buffered formalin fixation. Normal lymphoid samples from reactive lymph nodes, tonsil, spleen or thymus were used to compare.
Clinical information including age at the time of diagnosis, stage of the disease, site of tumor localization, lactate dehydrogenase (LDH) values and follow-up information from 40 peripheral T-cell lymphoma cases were collected from medical reports ( Table 1) . Most of the cases were treated with similar therapy protocols based on combination chemotherapy with or without anthracyclines.
Microarray analysis of gene expression
Gene expression analysis was performed using the CNIO Oncochip (v1.1a) that includes 7657 different cDNA clones corresponding to 6386 known genes and ESTs related with cancer process or tissue-specific genes. Construction of the Oncochip was described elsewhere, 21 and the list of genes on the array can be found online (www.bioinfo.cnio.es). In this study we selected for the analysis 135 sequence-verified clones, representing 109 genes, directly related to NF-kB pathway, including extracellular ligands, transmembrane receptors, adaptor proteins, signal transduction kinases, NF-kB complex family members and some NF-kB-responsive genes (for the list of genes, see Supplementary Information). In short, 2.5-5 mg of total RNA was used to synthesize amplified RNA (aRNA) using the Superscript System for cDNA synthesis (Gibco BRL) and the T7 Megascript in vitro transcription kit (Ambion, Austin, TX, USA). The aRNA from each test sample was labelled with Cy5 dUTP, and hybridized together with a reference, labelled with Cy3. As reference we used the aRNA obtained from the Universal Human RNA (Stratagene, La Jolla, CA, USA), which consists in a mix of different cancer cell lines. Hybridizations were performed at 421C for 15 h as described previously. 21 After washing, the slides were scanned using Agilent Array Scanner. Images were then analyzed with the GenePix 5.0 program (Axon Instruments Inc., Union City, CA, USA). The Cy5/Cy3 ratios were obtained in each experiment with the GenePix software, and then print-tip loess-based normalization was performed using DNMAD (http://dnmad.bioinfo.cnio.es/) tool. 22 Before normalization, bad spots or areas showing defects were manually flagged. Spots with intensities for both channels (sum of medians) lower than the sum of mean backgrounds were also discarded.
Additionally, unsupervised hierarchical clustering was performed using the SOTA program, 23 available in the Gene Expression Pattern Analysis Suite package (GEPAS) (http:// gepas.bioinfo.cnio.es/). To avoid expression effects due to nontumoral accompanying cells, gene expression data in tumors were normalized with expression obtained in a pool of 11 reactive lymph nodes.
Quantitative RT-PCR analysis
Five representative genes of the NF-kB pathway, the MAP3K14 (NIK), the NF-kB inhibitor alfa (IkBa) genes and three NF-kB targets, such as interferon gamma (IFNG), CFLAR (c-Flip) and the metalloproteinase 9 (MMP9), were analyzed by QT RT-PCR to validate the cDNA microarray expression data. Assays-onDemand Taqman MGB probes (Applied Biosystems) of these genes were used. All PCRs were performed using the ABI prism 7900 system (Applied Biosystems) under the conditions recommended by the manufacturers. To perform relative quantification of the expression of both genes, a standard curve was constructed with at least four different concentrations in triplicate using a cDNA obtained from the Universal Human RNA (Stratagene, La Jolla, CA, USA). The b-actin gene was used as control gene to test the quality of cDNAs. Expression was Table 1 Clinical characteristics of T-cell lymphomas involved in the NF-kB-positive and -negative subgroups 
Statistical analysis
To assess the differences between PTCL subtypes, Pearson w 2 tests were performed. Owing to the fact that ALCL lymphomas can be considered as an independent entity showing better survival times than other PTCL, the survival analysis was obtained either in all PTCL lymphomas or excluding the ALCL. Kaplan-Meier survival curves were used to estimate OS between the NF-kB-positive and -negative cases, and also for different clinical and pathological variables typically associated with prognosis. The log-rank test was used to compare survival curves. Univariate and multivariate Cox proportional hazards regression model was fit with the following variables: age of diagnosis, stage of disease, extranodal localization of tumor, LDH levels and the NF-kB-signature expression. The SPSS version 12.0 software was used for these analyses.
Results
Microarray expression of NF-kB pathway genes in PTCL
The clinical and histological heterogeneity showed by PTCL suggested molecular differences among these tumors. To evaluate if molecular differences in the NF-kB pathway could differ among PTCL tumors, we analyzed the expression of 109 NF-kB-related genes included in the CNIO-Oncochip cDNA microarray. The unsupervised hierarchical clustering analysis of PTCL and LBL primarily defined two different branches. One of them contained both LBL and a subset of the PTCL. This PTCL subgroup included nearly one-third (20/62 ca 5q5) of all PTCL and was characterized by generalized reduced expression of NF-kB pathway genes (Figure 1 ). For this reason, we defined this NF-jB expression in PTCL B Martínez-Delgado et al group as NF-kB-negative PTCL lymphomas. As shown in Figure 1 , NF-kB-negative PTCL presented a more similar expression pattern to that obtained by LBL. The other branch contained the rest of PTCL, which showed high expression of NF-kB genes, and we named them NF-kB-positive PTCL. Although NF-kB-positive PTCL clearly showed increased expression of NF-kB genes comparing to NF-kB-negative PTCL and LBL, this subgroup also contained two clusters, showing some degree of heterogeneity among NF-kB-positive PTCL tumors. Differences in expression of NF-kB genes between the NF-kB-positive and -negative cannot be explained by a different content of tumor cells within the samples, since the estimation of tumor cells in the tumor samples showed no significant differences in these two groups ( Table 1) . As the expression of the NF-kB pathway genes in PTCL tumors were normalized to the expression in reactive lymph nodes, this means that the NF-kB-positive PTCL tumors show higher expression, and the NF-kB-negative PTCL show lower expression of many of the NF-kB genes comparing with reactive lymph nodes. The average expression in reactive lymph nodes, LBL tumors, and in the two PTCL groups generated in the unsupervised clustering is shown in Figure 2 . Clearly, the reactive lymph nodes also showed high expression of some NFkB pathway genes as occurred in the NF-kB-positive PTCL subgroup, but the expression pattern was significantly different in the reactive samples and the tumors, indicating that the increased or decreased expression of at least some of these genes in PTCL samples could be related with the tumoral process.
Among genes overexpressed in the NF-kB-positive PTCL comparing to reactive nodes, we found some TNF family members such as TNF and TRAIL (TNFSF10), surface receptors CD2, CD30 (TNFRSF8), CD95/Fas (TNFRSF6), some kinases such as IRAK1 and TBK1, NF-kB complex members like NFkBIA or RELB and some responsive genes such as INFG, IL2RB and IL2RG, MMP-9 or VCAM1 (Figure 2) . However, most of the NF-kB-related genes showed a reduced expression in the NFkB-negative PTCL cases comparing to both NF-kB-positive PTCL and reactive nodes, but they showed higher expression of MYC oncogene, as occurred also in LBL lymphomas.
To study whether these two subgroups of PTCL were related with any particular pathological subtype of peripheral T-cell lymphoma, we looked at the distribution of the different peripheral T-cell lymphoma subtypes included in the study among the NF-kB-positive and -negative subgroups (Table 3) . Although there were no significant differences between NF-kBpositive and -negative tumors with regard to the distribution of T-cell lymphoma subtypes (P ¼ 0.374), it was observed that while the NF-kB-positive lymphomas included 67% of PTCL (not otherwise characterized) cases and 33% of other peripheral subtypes, the NF-kB-negative group included an increased number (45%) of these other subtypes (mainly ALCL lymphomas) (Table 3) .
Quantitative RT-PCR validation of NF-kB pathway genes
Among genes of the NF-kB pathway, the MAP3K14 (NIK) gene, one of the main kinases involved in the phosphorylation of the NF-kB inhibitors, the IkBa gene, one of the inhibitors of NF-kB complex and three target genes of NF-kB, IFNG, CFLAR and MMP9, were selected to analyze their expression by real-time RT-PCR. As occurred in the microarray expression analysis, we found significant differences between the expression of these genes in NF-kB-positive and -negative PTCL subgroups in all the analyzed genes excepting IkBa, which also showed higher expression in NF-kB-positive PTCL than in NF-kB-negative PTCL, although it did not reach statistical significance (Figure 3 ).
NF-kB p65 detection by immunohistochemistry
Immunohistochemical analysis was also performed for NF-kB p65/RelA to study whether the differences in the expression detected by microarray analysis could also be detected at a protein level. Most of the tumors (34/46) included in the T-cell lymphoma TMA were also included in the microarray expression analysis. Among the 46 lymphomas in the TMA, we obtained valuable results in 36 cases ( Table 2 ). The expression of NF-kB-p65 protein in positive cases was characterized by a Unsupervised clustering analysis with 135 cDNA clones corresponding to 109 NF-kB pathway genes. A subset of PTCL, defined as NF-kB-negative (NF-kBÀ), grouped together with LBL. Although both LBL and NF-kBÀ PTCL show reduced expression of NF-kB genes, LBL are clearly differentiated from PTCL tumors. In the other branch, the rest of PTCL lymphomas show higher expression of NF-kB genes, and were defined as NF-kB-positive (NF-kB þ ) lymphomas. strong cytoplasmatic and a weaker, although detectable, nuclear staining in tumoral cells (Figure 4) , while normal infiltrating lymphocytes showed in general a very strong cytoplasmic p65 staining.
The study of NF-kB activation based on the expression of p65/ RelA protein revealed differences in the intensity of this protein in different T-cell tumors. In all, 23/36 (64%) of the T-cell lymphomas showed high ( þ þ ) or very high ( þ þ þ ) levels of NF-kB p65 protein, and 13/36 (36%) showed low ( þ ) or no evidence of expression (À). Most of the PTCL unspecified lymphomas (13/15, 87%) showed important levels of p65 protein, being classified as highly or very highly expressed p65 cases. Among the other subtypes of PTCL, 3/4 (75%) cases of CTCL, 2/4 (50%) of AILT and 5/5 (100%) of NK/T lymphomas also showed high levels of NF-kB. However, a different behavior regarding NF-kB protein was found in ALCL tumors. In general, these lymphomas showed strong labelling of p65 protein in nontumoral cells accompanying the anaplastic tumoral cells. We evaluated the labelling in anaplastic cells only. Significantly, among ALCL (in contrast to what occurred in other PTCL subtypes), 6/7 (86%) lymphomas had low levels of NF-kB in anaplastic cells. With regard to LBL, all cases were clearly negative for NF-kB expression, two LBL tumors included in the TMA as well as four additional lymphoblastic lymphomas and seven lymphoblastic cell lines (Table 2) , confirming the results obtained in the microarray expression analysis. 3 All lymphomas, except one CTCL case (TA-40), showing high or very high expression of NF-kB p65 protein by IHC, were also classified as NF-kB-positive by microarray expression analysis. However, most ALCL cases showed low expression of p65 protein by IHC, but were classified in the NF-kB-positive group by microarray analysis. This could be explained by the high expression of NF-kB protein among nontumoral cells accompanying anaplastic cells in these tumors, which contributed to misclassify them as NF-kB-positive tumors. Moreover, two AILT lymphomas (TA-23 and TA-24) were classified as NF-kBpositive tumors by the microarray expression analysis, but both showed low NF-kB p65 protein in tumoral cells. In these cases, we identified a high number of CD20-positive cells within the tumor, which were probably responsible for the high expression of NF-kB genes detected by microarray expression analysis. For this reason, we reconsidered these tumors as NF-kB-negative lymphomas for subsequent survival analysis.
Figure 2
Average expression patterns of reactive lymph nodes, NF-kB-positive PTCL, NF-kB-negative PTCL groups and LBL lymphomas. Differences in the average expression among these groups are shown. Reactive lymph nodes as well as NF-kB-positive PTCL show increased expression of NF-kB genes, comparing with NF-kB-negative PTCL and LBL. However, the most highly expressed genes in normal lymph nodes do not correspond with the most highly expressed genes in NF-kB þ PTCL. The clone ID and the gene symbol of the genes included in the analysis are represented on the right side. As the presence of nontumoral cells within the tumors, which could be also expressing NF-kB genes, could contribute to misclassify some tumors, the expression data were first normalized with the expression of NF-kB pathway genes in the reactive lymph nodes. Although most of the tumors were localized in lymph nodes, some had extranodal origin. Then, we compared 
Figure 3
Box plots representing expression values of NIK, IkBa, IFNG, CFLAR and MMP9 genes by real-time RT-PCR in both groups of PTCL defined by microarray expression analysis, NF-kBÀ and NF-kB þ . Boxes represent the quartiles, median is represented by a white line within the box, circles show atypical values (1.5-3 times the length of the box) and asterisks show extreme values (more than three times the box). Significant differences in the expression of almost all these genes among NF-kBÀ and NF-kB þ groups were found.
Figure 4
Immunohistochemical analysis of NF-kB p65 in representative PTCL. Expression of NF-kB p65 protein showed differences between NF-kB-positive PTCL lymphomas (a, b) and NF-kB-negative PTCL (c, d). Nuclear staining of p65 in positive and negative cases is evidenced at higher magnification in the top right corner of each panel (image magnifications were Â 20 and Â 40).
if the localization site of the tumors differs between NF-kBpositive and -negative lymphomas. In both cases, most of the tumors, 85% (36/42) in NF-kB-positive and 65% (13/20) in NF-kBnegative, corresponded to nodal cases, indicating that although in some cases (some AILT lymphomas) the underlying nontumoral cells could contribute to increase the NF-kB expression, the differentiation between NF-kB-positive and -negative PTCL might be reflecting also differences in the tumor cells.
Reduced expression of NF-kB pathway genes correlates with lower survival times
We assessed the value of the expression of NF-kB pathway genes included in the microarray analysis in the prognosis of PTCL. Given that some ALCL (ALK1 positive) could be considered to have better survival times, we performed the survival analysis in PTCL tumors both including or excluding ALCL. However, we did not find significant differences in the survival analysis results including or excluding ALCL lymphomas from the analysis, perhaps because most of the ALCL in this study were ALK1-negative. Kaplan-Meier estimation of OS between NF-kB-positive and -negative lymphomas is shown in Figure 5 , revealing significant differences between survival curves in these two subgroups (P ¼ 0.032). For the patients with NF-kB-positive T-cell lymphomas, the median OS was 25 months and mean OS was 66 months (range 0-124 months), compared with a median OS of 12 months and a mean of 11 months (range 0-19 months) for the NF-kB-negative lymphomas. Since all patients were treated with equivalent chemotherapy protocols, it is not likely that treatment differences can explain survival differences.
The univariate analysis performed for different variables traditionally related with survival in T-cell lymphomas revealed that age of diagnosis, over or under 60 years (P ¼ 0.010), stage of disease, stages I-II or III-IV (P ¼ 0.002), were significantly associated with a shorter survival, while LDH, high or normal levels (P ¼ 0.078) and extranodal localization (P ¼ 0.219) were not found to be significant. The reduced expression of the NF-kB signature was also significantly associated with shorter survival times in the univariate analysis (P ¼ 0.042).
All variables found to be significant in the univariate analysis, together with NF-kB signature expression, were used for multivariate analysis. The stage of the disease was the most important variable influencing OS in PTCL (P ¼ 0.001). The results also revealed that low expression of the NF-kB pathway genes is an independent prognostic factor associated to shorter OS (P ¼ 0.022). Similar results were obtained when ALCL were removed from the analysis (Table 4) .
Discussion
The clinical and histological heterogeneity showed by PTCL lymphomas suggests molecular differences among these tumors. Over the last 4 years, DNA microarrays have allowed the identification of expression profiles of different cancer types and the stratification of a given tumor into different clinically significant subtypes. [25] [26] [27] In a previous study, we identified the general expression profile of different subtypes of T-cell lymphomas, including PTCL and LBL subgroups. We found that expression of NF-kB pathway genes differed greatly in PTCL and LBL, with a reduced expression of these genes in all LBL tumors Kaplan-Meier survival curves of NF-kB-positive and -negative PTCL cases defined by microarray expression analysis. Significant differences in survival curves were found between these PTCL subgroups. However, we could not establish significant differences among PTCL subtypes. Using an increased number of PTCL cases, we explored whether NF-kB pathway gene expression could also help us to differentiate among PTCL lymphomas. In fact, NF-kB activity has been proven to be a factor allowing the differentiation between two groups of DLBCL with distinct prognosis. 13 We found that one-third of PTCL formed a clearly defined subgroup showing reduced expression of NF-kB pathway genes, as occurred in LBL. Different experiments, including our previous work on T-cell lymphomas, 3 demonstrated low NFkB activity in some T-lymphoblastic cell lines compared to peripheral cell lines. 28 These results indicate that microarray expression analysis could be very helpful in identifying the involvement of specific molecular pathways in the development of some tumors.
In T lymphocytes, NF-kB family members are important for their maturation and survival and induce the expression of gene products mediating innate and adaptive immunity. After the antigen encounter T cells, proliferative and survival pathways are initiated mediated by TCR signalling together with costimulatory signals, which induce activation of NF-kB and then regulate the expression of growth-promoting cytokines such us IL-2. 29, 30 Moreover, experiments performed using CD4 þ cells from p50À/À and cRelÀ/À mice demonstrated that NF-kB activation by TCR is necessary and sufficient for T-cell survival. 31 As activated normal T lymphocytes present activation of NF-kB pathway, it is likely that the high expression of NF-kBrelated genes in some PTCL lymphomas could reflect a physiological condition of T-cells. In our study, to obtain the NF-kB expression profiles, expression values in tumors were normalized with that of reactive lymph nodes. Thus, the NF-kBpositive subset of PTCL seems to have higher expression than reactive samples, while NF-kB-negative tumors presented reduced expression of these genes. Interestingly, NF-kB-negative PTCL also showed reduced expression of characteristic T-cell markers, such as CD2, CD3, CD4 or CD5, indicating that this subset of lymphomas are losing some of the main features characterizing T-cells, and then could resemble a loss of differentiation of tumoral cells. It is also possible that the NFkB-positive PTCLs have an increased activity of this pathway independently of the physiological activation of this factor, leading to an oncogenic effect of NF-kB in these tumors mainly through transcriptional activation of genes that suppress apoptosis and promote cell growth. 7 Constitutive activation of NF-kB has been described in other types of lymphoma, such as Hodgkin's lymphomas 20, 32 and mycosis fungoides, a subtype of cutaneous T lymphoma. 14 Here we found that high expression of NF-kB pathway genes is a feature not restricted to any of the categories of peripheral T lymphomas. Excluding ALCL lymphomas, most PTCL, 72% of PTCL unspecified, 71% of AILT and 50% of CTCL and 60% of NK/T lymphomas, showed increased levels of some NF-kB-related genes. It is possible that these percentages could be, in some way, overestimated, for example, in some cases with an important number of nontumoral cells accompanying the tumor cells. However, normal lymphoid samples, although they showed high expression of a number of NF-kB pathway genes analyzed, had a significantly different expression profile than the tumors, indicating that the activation of NF-kB in normal and tumoral samples could be related to overexpression of different genes.
In addition, differences in the NF-kB expression in the two groups of PTCL defined by the microarray data were confirmed by IHC analysis. ALCL, in contrast to the other subtypes of PTCL, were characterized by low expression of NF-kB p65 in the anaplastic tumoral cells comparing with the expression in the nontumoral cells accompanying the tumor. In this sense, the inclusion of some ALCL into the NF-kB-positive subgroup in the microarray expression analysis could be due to the contribution of the nontumoral cells present in the tumor in which we found expression of NF-kB p65 protein.
We found that the differentiation between NF-kB-positive and -negative PTCL obtained by microarray expression analysis could be of clinical interest. Among these cases, the expression profile associated with a reduced expression of NF-kB pathway genes was significantly associated with shorter survival of patients, in contrast with longer survival times showed by the NF-kB-positive lymphomas. Moreover, this variable seems to be an independent prognostic factor when evaluated alongside other clinical variables commonly associated to survival, such as age, or advanced stage of disease. Then, the expression of NFkB-related genes distinguishes between two clinically different subgroups within a heterogeneous category. Previous studies described that overexpression of NF-kB target genes characterized a subgroup of DLBCL with more aggressive features and poorer survival. 12, 13 In contrast, we found the group of NF-kBnegative PTCL associated to worse survival. Although there are many evidences indicating that activation of NF-kB could lead to tumorigenesis, there are also examples in which suppressing NF-kB could be tumorigenic. Downregulation of NF-kB and Fas expression protects melanoma cell lines against UV-induced apoptosis 33 and, also, blockade of NF-kB predisposes murine skin to squamous cell carcinoma. 34 Then, the opposite effects of NF-kB, proliferative and antiapoptotic or apoptotic, could be dependent on the cell type or the nature of the signals, leading to activation of different pathways. The worse prognosis associated to the NF-kB-negative PTCL lymphomas could be indicating that different oncogenic events could be involved in this subset of tumors, conferring more aggressive features. The differentiation of PTCL by their NF-kB profile might be of interest in relation to therapy. Inhibition of NF-kB in parallel with certain chemotherapy treatments enhances the apoptotic potential of the chemotherapy. 7 Then, the differentiation of PTCL by their NF-kB profile might be considered in future in order, for example, to apply NF-kB inhibition as an adjuvant therapy.
Conclusion
In summary, microarray expression profiling of NF-kB pathway genes in peripheral T-cell lymphomas allowed us to differentiate between high or low expressing NF-kB tumors. Importantly, this differentiation could be of clinical interest, since our results revealed that reduced NF-kB expression was associated with worse OS of peripheral T lymphoma patients. thank the CNIO Tumour Bank for help in providing tumour samples.
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